このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Vir Biotechnology 将来の成長

Future 基準チェック /26

Vir Biotechnologyの収益は年間1.6%で減少すると予測されていますが、年間収益は年間23.9%で増加すると予測されています。EPS は年間増加すると予測されています。自己資本利益率は 3 年後に-56% 6.5%なると予測されています。

主要情報

-1.6%

収益成長率

6.5%

EPS成長率

Biotechs 収益成長	24.4%
収益成長率	23.9%
将来の株主資本利益率	-56.0%
アナリストカバレッジ	Good
最終更新日	09 Jun 2024

今後の成長に関する最新情報

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates

May 05

Recent updates

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates

May 05

Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Slashed This Year's Revenue Estimates By 37%

Aug 07

Revenues Working Against Vir Biotechnology, Inc.'s (NASDAQ:VIR) Share Price Following 42% Dive

Jul 24

Analysts Just Shaved Their Vir Biotechnology, Inc. (NASDAQ:VIR) Forecasts Dramatically

Feb 28

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Could Be 26% Below Their Intrinsic Value Estimate

Jan 07

Vir Biotechnology: Focus On Hepatitis B Development Could End Up Paying Off

Oct 12

Vir Biotech gains 12% as U.S. govt. inks multi-year deal worth up to $1B

Oct 04

Vir begins dosing in mid-stage study of VIR-2218, VIR-3434 for hepatitis D virus

Sep 22

Vir Biotechnology falls 15% on Q2 revenue miss impacted by ~$400M for potential write-offs

Aug 09

Vir: Biotechnology's Best Near-Term Capital Gain Prospect

Jul 27

業績と収益の成長予測

NasdaqGS:VIR - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	56	-606	-473	-436	7
12/31/2025	39	-579	-430	-395	8
12/31/2024	80	-485	-358	-326	8
3/31/2024	80	-539	-779	-762	N/A
12/31/2023	86	-615	-800	-779	N/A
9/30/2023	119	-601	-668	-636	N/A
6/30/2023	491	-262	-410	-362	N/A
3/31/2023	446	-144	928	987	N/A
12/31/2022	1,616	516	1,595	1,663	N/A
9/30/2022	2,379	1,143	1,567	1,636	N/A
6/30/2022	2,108	1,078	1,357	1,412	N/A
3/31/2022	2,326	1,216	555	592	N/A
12/31/2021	1,095	529	-69	-48	N/A
9/30/2021	284	-102	-149	-137	N/A
6/30/2021	183	-297	-88	-81	N/A
3/31/2021	73	-390	-238	-232	N/A
12/31/2020	76	-299	-197	-191	N/A
9/30/2020	76	-257	-153	-148	N/A
6/30/2020	75	-220	-140	-135	N/A
3/31/2020	10	-223	-155	-149	N/A
12/31/2019	8	-175	-139	-130	N/A
9/30/2019	10	-137	-130	-120	N/A
6/30/2019	12	-122	-128	-118	N/A
3/31/2019	12	-117	-119	-109	N/A
12/31/2018	11	-116	-104	-94	N/A
12/31/2017	3	-70	N/A	-66	N/A

アナリストによる今後の成長予測

収入対貯蓄率: VIR今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: VIR今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: VIR今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: VIRの収益 ( 23.9% ) US市場 ( 8.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: VIRの収益 ( 23.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: VIR 3 年以内に赤字になると予測されています。

Vir Biotechnology 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 78%

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates

Price target increased by 12% to US$29.50

Price target decreased by 32% to US$18.00

Price target decreased by 10% to US$26.50

Price target decreased by 9.2% to US$29.75

Recent updates

New minor risk - Share price stability

Vir Biotechnology, Inc. Announces New Preliminary Data from its Phase 2 SOLSTICE Hepatitis Delta Clinical Trial Evaluating tobevibart, an Investigational Monoclonalantibody, and Elebsiran

Vir Biotechnology, Inc. Appoints Mark D. Eisner as Executive Vice President and Chief Medical Officer, Effective June 3, 2024

Consensus revenue estimates increase by 78%

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders

Vir Biotechnology, Inc., Annual General Meeting, May 29, 2024

Vir Biotechnology, Inc., Annual General Meeting, May 29, 2024

Vir Biotechnology, Inc. to Report Q1, 2024 Results on May 02, 2024

CEO & Director recently sold US$690k worth of stock

Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule

Director notifies of intention to sell stock

Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Director notifies of intention to sell stock

Price target increased by 12% to US$29.50

Vir Biotechnology, Inc. Announces Phil Pang Will Step Down as Chief Medical Officer

Price target decreased by 32% to US$18.00

Vir Biotechnology, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Price target decreased by 10% to US$26.50

Sticking With Vir Biotechnology

Price target decreased by 9.2% to US$29.75

Price target decreased by 9.2% to US$29.75

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Vir Biotechnology, Inc. Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer

Vir Biotechnology, Inc. Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s the Liver Meeting® 2023

Vir Biotechnology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Biomedical Advanced Research and Development Authority Awards Funding to Vir Biotechnology, Inc. to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats

Vir Biotechnology, Inc. Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV

New major risk - Revenue and earnings growth

Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Slashed This Year's Revenue Estimates By 37%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Vir Biotechnology, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Revenues Working Against Vir Biotechnology, Inc.'s (NASDAQ:VIR) Share Price Following 42% Dive

Consensus revenue estimates fall by 36%

Vir Biotechnology, Inc. Announces Topline Data from Phase 2 Peninsula Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness

Price target decreased by 24% to US$36.38

New minor risk - Share price stability

Independent Chairman notifies of intention to sell stock

Vir Biotechnology, Inc. Announces the Appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer, Effective July 10, 2023

Vir Biotechnology, Inc. Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D

Independent Director notifies of intention to sell stock

Vir Biotechnology, Inc. Elects Elliott Sigal as Director

Vir Biotechnology, Inc. Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer

Vir Biotechnology, Inc. Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNa and an NRTI

Consensus EPS estimates fall by 12%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP & Chief Technology Officer recently sold US$60k worth of stock

Independent Chairman notifies of intention to sell stock

Price target decreased by 7.5% to US$48.13

Analysts Just Shaved Their Vir Biotechnology, Inc. (NASDAQ:VIR) Forecasts Dramatically

Full year 2022 earnings released: EPS: US$3.89 (vs US$4.07 in FY 2021)

President notifies of intention to sell stock

Executive VP recently sold US$61k worth of stock

Vir Biotechnology, Inc. to Report Q4, 2022 Results on Feb 23, 2023

President notifies of intention to sell stock

Now 22% undervalued after recent price drop

Executive VP exercised options and sold US$836k worth of stock

Vir Biotechnology, Inc. Announces CEO Changes

Price target increased by 8.5% to US$50.75

Investor sentiment improves as stock rises 16%

Independent Chairman notifies of intention to sell stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Could Be 26% Below Their Intrinsic Value Estimate

Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A

Independent Chairman notifies of intention to sell stock

Independent Chairman notifies of intention to sell stock

Insufficient new directors

Independent Chairman notifies of intention to sell stock